Peer-Reviewed Publications

      Systems toxicology meta-analysis – From aerosol exposure to nanotoxicology

      Talikka, M.; Belcastro, V.; Gubian, S.; Martin, F.; Peitsch, M. C.; Hoeng, J.
      Published
      Apr 11, 2019
      DOI
      10.1016/j.cotox.2019.03.010
      Link to publication
      Topic
      Summary

      Systems toxicology marks an important stage in the evolution of toxicology. It combines the insights from traditional toxicology endpoints, high-throughput data, and quantitative analysis of large cause-and-effect molecular network models that provide the most mechanistic information in the interpretation of high-throughput data. Here, we show an example how pulmonary causal biological network models can be used in a meta-analysis of independent studies on engineered nanomaterials (ENM) to gain mechanistic insight into the similarities and differences of the ways the ENMs impact biological processes in the mouse lung. Meta-analyses using the lung network models could be used in various toxicological applications to find underlying trends in response to exposures, derive compound-specific mechanistic signatures, and translate between species.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.